ALX Oncology Holdings Inc.
ALXO
$0.55
-$0.01-1.79%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.39% | -13.72% | -8.23% | -5.95% | -1.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.33% | 3.50% | 30.97% | 30.35% | 33.62% |
| Operating Income | 16.33% | -3.50% | -30.97% | -30.35% | -33.62% |
| Income Before Tax | 16.14% | -3.55% | -31.57% | -28.77% | -30.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.14% | -3.50% | -31.50% | -28.71% | -30.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.14% | -3.50% | -31.50% | -28.71% | -30.23% |
| EBIT | 16.33% | -3.50% | -30.97% | -30.35% | -33.62% |
| EBITDA | 16.58% | -3.29% | -30.83% | -30.05% | -33.14% |
| EPS Basic | 30.38% | 16.44% | -13.85% | -17.20% | -23.35% |
| Normalized Basic EPS | 30.37% | 16.40% | -13.90% | -17.24% | -23.40% |
| EPS Diluted | 30.38% | 16.44% | -13.85% | -17.20% | -23.35% |
| Normalized Diluted EPS | 30.37% | 16.40% | -13.90% | -17.24% | -23.40% |
| Average Basic Shares Outstanding | 20.69% | 24.44% | 17.68% | 11.09% | 5.57% |
| Average Diluted Shares Outstanding | 20.69% | 24.44% | 17.68% | 11.09% | 5.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |